Evelo Biosciences Inc (EVLO) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Evelo Biosciences Inc (NASDAQ:EVLO) have been given an average recommendation of “Buy” by the eight ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $21.80.
Several brokerages recently commented on EVLO. Zacks Investment Research raised Evelo Biosciences from a “sell” rating to a “hold” rating in a report on Monday, April 29th. Chardan Capital reissued a “hold” rating and set a $10.00 target price on shares of Evelo Biosciences in a report on Thursday, May 2nd. Jefferies Financial Group began coverage on Evelo Biosciences in a report on Tuesday, April 30th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Cowen reissued a “buy” rating on shares of Evelo Biosciences in a report on Thursday, May 2nd.
Large investors have recently made changes to their positions in the stock. Northern Trust Corp boosted its holdings in shares of Evelo Biosciences by 6.9% during the 1st quarter. Northern Trust Corp now owns 136,998 shares of the company’s stock worth $1,096,000 after buying an additional 8,843 shares during the period. State of Wisconsin Investment Board acquired a new stake in Evelo Biosciences in the 1st quarter worth about $151,000. New York State Common Retirement Fund raised its stake in Evelo Biosciences by 47.9% in the 1st quarter. New York State Common Retirement Fund now owns 10,800 shares of the company’s stock worth $86,000 after purchasing an additional 3,500 shares in the last quarter. Rhumbline Advisers acquired a new stake in Evelo Biosciences in the 1st quarter worth about $122,000. Finally, Larson Financial Group LLC raised its stake in Evelo Biosciences by 29.5% in the 1st quarter. Larson Financial Group LLC now owns 7,268 shares of the company’s stock worth $58,000 after purchasing an additional 1,655 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.
Evelo Biosciences (NASDAQ:EVLO) last announced its earnings results on Thursday, May 2nd. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.09). Sell-side analysts forecast that Evelo Biosciences will post -2.61 earnings per share for the current fiscal year.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.
Recommended Story: What is Cost of Debt?
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.